Immunic, Inc

(NASDAQ:IMUX)

Latest On Immunic, Inc (IMUX):

Date/Time Type Description Signal Details
2023-05-16 00:53 ESTNewsImmunic: Proof Of Concept With IMU-856 Provides Additional Shot On GoalN/A
2023-05-14 21:40 ESTNewsImmunic, Inc. (IMUX) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 20:55 ESTNewsImmunic GAAP EPS of -$0.58 misses by $0.06N/A
2023-05-09 00:52 ESTNewsImmunic gains after early-stage data for bowel disease candidateN/A
2023-05-04 13:06 ESTNewsImmunic's celiac disease drug shows promise in ongoing phase 1 trialN/A
2023-04-05 23:34 ESTNewsImmunic surges ~20% as IMU-838 shows promise in ulcerative colitis trialN/A
2023-02-23 15:53 ESTNewsImmunic GAAP EPS of -$3.78 misses by $0.88N/A
2023-02-23 15:52 ESTNewsImmunic, Inc. (IMUX) Q4 2022 Earnings Call TranscriptN/A
2023-02-22 14:01 ESTNewsImmunic FY 2022 Earnings PreviewN/A
2023-02-07 20:13 ESTNewsImmunic: Multiple Sclerosis Data In H2 2023 Could Provide Major ShiftN/A
2023-01-31 16:39 ESTNewsImmunic adds 14% as Wedbush initiates with bullish view on lead assetN/A
2022-12-28 13:41 ESTNewsImmunic: Revisiting A 'Lottery Ticket'N/A
2022-11-17 22:38 ESTNewsImmunic rises 15% as drug prevents/delays worsening of MS patients in long term trial dataN/A
2022-11-06 09:01 ESTNewsImmunic, Inc. (IMUX) Q3 2022 Earnings Call TranscriptN/A
2022-11-03 10:34 ESTNewsImmunic GAAP EPS of -$0.69 misses by $0.03N/A
2022-11-02 18:42 ESTNewsImmunic Q3 2022 Earnings PreviewN/A
2022-10-20 17:37 ESTNewsImmunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placeboN/A
2022-10-12 21:36 ESTNewsImmunic: New MS Drugs Need Extreme Product DifferentiationN/A
2022-10-10 13:26 ESTNewsImmunic stock gains on $60M oversubscribed PIPE financingN/A
2022-08-07 02:12 ESTNewsImmunic, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-07 02:12 ESTNewsImmunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 12:26 ESTNewsImmunic GAAP EPS of -$0.72 in-lineN/A
2022-06-15 10:02 ESTNewsImmunic rises on publication of trial results for lead asset in multiple sclerosisN/A
2022-06-02 10:09 ESTNewsImmunic stock crashes 62% as lead asset IMU-838 fails mid-stage study in ulcerative colitisN/A
2022-05-12 00:35 ESTNewsImmunic, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-11 04:51 ESTNewsImmunic Inc. (IMUX) CEO Daniel Vitt on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-10 07:12 ESTNewsImmunic GAAP EPS of -$0.74 beats by $0.05N/A
2022-03-17 12:03 ESTNewsImmunic promotes internal candidate to CFO roleN/A
2022-02-24 13:55 ESTNewsImmunic GAAP EPS of -$3.93 misses by $0.04N/A
2022-02-24 13:55 ESTNewsImmunic, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-02-24 13:55 ESTNewsImmunic Inc. (IMUX) CEO Daniel Vitt on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-23 18:55 ESTNewsImmunic FY 2021 Earnings PreviewN/A
2021-11-06 22:00 ESTNewsImmunic, Inc. (IMUX) CEO Daniel Vitt on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 10:47 ESTNewsImmunic EPS beats by $0.02N/A
2021-11-02 17:41 ESTNewsWarning: IMUX is at high risk of performing badlyN/A
2021-10-28 23:19 ESTNewsImmunic completes enrollment in mid-stage IMU-838 ulcerative colitis studyN/A
2021-10-14 19:42 ESTNewsImmunic hires Patrick Walsh as Chief Business OfficerN/A
2021-09-30 16:30 ESTNewsEnrollment underway in Immunic's mid-stage study of IMU-838 in progressive multiple sclerosisN/A
2021-09-23 04:56 ESTNewsImmunic inks license deal for DHODH inhibitors in viral infections, including COVID-19N/A
2021-08-07 01:16 ESTNewsImmunic EPS misses by $0.15N/A
2021-07-21 11:54 ESTNewsImmunic stock gains 6% on FDA go ahead for IMU-838 trials in multiple sclerosisN/A
2021-07-21 11:48 ESTNewsImmunic announces common stock public offeringN/A
2021-07-21 11:48 ESTNewsRFIL, KC, IMUX and GBS among after-hours moversN/A
2021-07-21 11:48 ESTNewsImmunic slips on pricing $45M equity offeringN/A
2021-07-21 11:47 ESTNewsImmunic (IMUX) Updates On The Preclinical And Clinical Development Of IMU-935 - SlideshowN/A
2021-05-06 13:45 ESTNewsImmunic EPS misses by $0.95N/A
2021-03-17 02:00 ESTNewsImmunic (IMUX) Presents At 33rd Annual Roth ConferenceN/A
2021-03-01 11:47 ESTEarnings EstimateAn EPS average of -$3.20 is estimated for the 2022 year.Sell
2021-03-01 11:47 ESTEarnings EstimateAn EPS average of -$0.65 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-28 11:52 ESTFinancialsCompany financials have been released.Neutral

About Immunic, Inc (IMUX):

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

IMUX Quotes by TradingView

See Advanced Chart

General

  • Name Immunic, Inc
  • Symbol IMUX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 28
  • Last Split Factor1:40
  • Last Split Date2019-04-15
  • Fiscal Year EndDecember
  • IPO Date2014-04-17
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.immunic-therapeutics.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.04
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.89
  • Next Year EPS Estimate -$3.67
  • Next Quarter EPS Estimate -$0.63
  • Return on Assets -26%
  • Return on Equity -41%
  • Earnings Per Share -$11.31
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 320.91 million
  • EBITDA -18572000
  • Analyst Target Price $60.83
  • Book Value Per Share $7.50
View More

Share Statistics

  • Shares Outstanding 21.17 million
  • Shares Float 14.34 million
  • % Held by Insiders 2795%
  • % Held by Institutions 46.78%
  • Shares Short 1.31 million
  • Shares Short Prior Month 897720
  • Short Ratio 3.9
  • Short % of Float 9%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • 52 Week High $28.21
  • 52 Week Low $4.9
  • 50 Day Moving Average 17.33
  • 200 Day Moving Average 17.52
View More

Dividends

  • Dividend Date 2019-04-15
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Immunic, Inc (IMUX) Dividend Calendar:

IMUX's last dividend payment was made to shareholders on April 15, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Immunic, Inc (IMUX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.46-$0.6225.2%
2020-09-302020-11-05$N/A-$0.70-$0.65-8.24%
2020-06-302020-08-02$N/A-$0.90-$0.73-23.85%
2020-03-312020-05-08$N/A-$0.79-$0.9617.28%
2019-12-312020-03-16$N/A-$0.75-$0.761.32%
2019-09-302019-11-07$N/A-$0.82-$0.65-26.15%
2019-06-302019-08-08$N/A-$1.52-$0.68-123.53%
2019-03-312019-06-21$N/A-$8.69-$0.59-1372.25%
2018-12-312019-03-04$N/A-$2.33
2018-09-302018-11-07$N/A-$11.20-$11.200%
2018-06-302018-08-07$N/A-$12.00-$13.209.09%
2018-03-312018-05-08$N/A-$13.60-$13.600%
2017-12-312018-03-13$N/A-$14.00-$12.40-12.9%
2017-09-302017-10-25$N/A-$12.00-$12.806.25%
2017-06-302017-08-03$N/A-$11.60-$14.1317.91%
2017-03-312017-05-09$N/A-$15.60-$14.60-6.85%
2016-12-312017-03-07$N/A-$0.37-$0.35-5.71%
2016-09-302016-11-03$N/A-$0.32-$0.320%
2016-06-302016-08-02$N/A-$0.30-$0.339.09%
2016-03-312016-05-09$N/A-$0.31-$0.28-10.71%
2015-12-312016-03-08$N/A-$0.34-$0.4219.05%
2015-09-302015-11-05$N/A-$0.51-$0.5812.07%
2015-06-302015-07-30$N/A-$0.63-$0.62-1.61%
2015-03-312015-05-12$N/A-$0.62-$0.620%
2014-12-312015-03-19$N/A-$0.59-$0.58-1.72%
2014-09-302014-11-13$N/A-$0.59-$0.636.35%
2014-06-302014-08-06$N/A-$36.40-$22.02-65.3%
2014-03-312014-05-29$N/A-$979.60-$20.78-4614.15%

Immunic, Inc (IMUX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development -66.1 million 11.04 million 9.99 million N/A 6.03 million
Income Before Tax -11.16 million -12.91 million -11.46 million N/A -7.69 million
Selling General Administrative -17.65 million 2.51 million 2.24 million N/A 10.26 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -11.16 million -13.55 million -12.22 million N/A -16.29 million
Operating Income -14.19 million -13.55 million -12.22 million N/A -16.29 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A 760000 N/A 8.6 million
Net Income From Continuing Operations -11.16 million -12.91 million -11.46 million N/A -7.69 million
Net Income Applicable to Common Shares -11.16 million -12.91 million -11.46 million -8.49 million -7.69 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities 40000 297000 -973000 -1.38 million 2.34 million
Total Cash Flow from Investing Activities -63000 -55000 -4000 -25000 1.24 million
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 96.54 million N/A N/A 4.71 million 223000
Change to Operating Activities N/A 1.56 million -1.94 million 2.46 million 19000
Change in Cash 84.57 million N/A N/A -1.09 million -5.66 million
Total Cash from Operating Activities -11.91 million -9.23 million -11.03 million -6.27 million -5.98 million
Depreciation 43000 N/A N/A 12000 9000
Other Cash Flow from Investing Activities N/A N/A N/A N/A -75000
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A 37000 N/A -74000 -21000
Change to Net Income 707000 369000 353000 330000 -130000
Capital Expenditures 63000 N/A N/A 25000 13000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 9.08 million N/A 8.47 million N/A 7.59 million
Total Stockholder Equity 158.79 million N/A 78.69 million N/A 58.36 million
Other Current Liabilities 379000 358000 361000 N/A 1.35 million
Total Assets 167.86 million N/A 87.15 million N/A 65.96 million
Common Stock 2000 2000 1000 1000 1000
Other Current Assets 6.29 million 4.36 million 655000 N/A 2.86 million
Retained Earnings -103.93 million -92.77 million -79.86 million -68.4 million -59.91 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A 42000 42000 42000 42000
Cash 127.45 million N/A 48.61 million N/A 29.37 million
Total Current Liabilities 8.4 million 8.03 million 7.67 million N/A 7.07 million
Other Stockholder Equity -4.11 million -1.75 million -1.61 million -1.68 million -1.37 million
Property, Plant & Equipment 203000 1.09 million 1.12 million 681000 713000
Total Current Assets 133.75 million 137.54 million 53.02 million N/A 32.23 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 125.82 million 129.91 million 45.72 million 17.52 million 25.39 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 8.02 million 3.42 million 1.73 million N/A 2.42 million

Immunic, Inc (IMUX) Chart:

Immunic, Inc (IMUX) News:

Below you will find a list of latest news for Immunic, Inc (IMUX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Immunic, Inc (IMUX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-07-170.50.45CALL0 19630TRUE00
2026-07-1710.2CALL0 9300TRUE00
2026-07-171.50.1CALL0 16850TRUE00
2026-07-1720.07CALL0 22820TRUE00
2026-07-172.50CALL0 0310.95TRUE00
2026-07-1750CALL0 0363.8TRUE00
2026-07-177.50CALL0 0114.12TRUE00
2026-07-17100CALL0 14122.15TRUE00
2026-07-1712.50CALL0 17120.85TRUE00
2026-07-17151.5CALL5 30124.56FALSE-0.18-0.11
2026-07-1717.50CALL0 4123.24FALSE00
2026-07-17200CALL0 117101.44FALSE00
2026-07-1722.50CALL0 18282.76FALSE00
2026-07-17250CALL0 2165.27FALSE00
2026-07-170.50PUT0 00FALSE00
2026-07-1710.25PUT0 3600FALSE00
2026-07-171.50PUT0 1380FALSE00
2026-07-1721.14PUT0 410FALSE00
2026-07-172.50PUT0 0379.4FALSE00
2026-07-1750PUT0 0306.66FALSE00
2026-07-177.50.22PUT2 72143.82FALSE0.220
2026-07-17100PUT0 117134.79FALSE00
2026-07-1712.51.24PUT3 23119.71FALSE0.060.05
2026-07-17150PUT0 5144.28TRUE00
2026-07-1717.50PUT0 0137.93TRUE00
2026-07-17200PUT0 0142.98TRUE00
2026-07-1722.50PUT0 0142.39TRUE00
2026-07-17250PUT0 0145.85TRUE00
2026-08-212.50CALL0 0202.02TRUE00
2026-08-2150CALL0 0112.58TRUE00
2026-08-217.50CALL0 0155.66TRUE00
2026-08-21100CALL0 0130.7TRUE00
2026-08-2112.50CALL0 0128.58TRUE00
2026-08-21150CALL0 0132.91FALSE00
2026-08-2117.50CALL0 0149.23FALSE00
2026-08-21200CALL0 0170.29FALSE00
2026-08-2122.50CALL0 0189.76FALSE00
2026-08-21250CALL0 0209.28FALSE00
2026-08-212.50PUT0 01153.08FALSE00
2026-08-2150PUT0 0465.55FALSE00
2026-08-217.50PUT0 0310.69FALSE00
2026-08-21100PUT0 0217.18FALSE00
2026-08-2112.50PUT0 0150.35FALSE00
2026-08-21150PUT0 0136.7TRUE00
2026-08-2117.50PUT0 0137.58TRUE00
2026-08-21200PUT0 0133.91TRUE00
2026-08-2122.50PUT0 0136.85TRUE00
2026-08-21250PUT0 0134.44TRUE00
2026-10-160.50.5CALL0 1020TRUE00
2026-10-1610.35CALL0 3720TRUE00
2026-10-161.50.2CALL0 2440TRUE00
2026-10-1620.05CALL0 610TRUE00
2026-10-162.50CALL0 0137.09TRUE00
2026-10-1650CALL0 1175.6TRUE00
2026-10-167.50CALL0 2145.27TRUE00
2026-10-16100CALL0 23143.68TRUE00
2026-10-1612.50CALL0 3137.32TRUE00
2026-10-16150CALL0 4137.68FALSE00
2026-10-1617.53.2CALL0 33110.51FALSE00
2026-10-16200CALL0 0114.33FALSE00
2026-10-1622.50CALL0 10115.64FALSE00
2026-10-16250CALL0 4108.22FALSE00
2026-10-160.50.25PUT0 510FALSE00
2026-10-1610.3PUT0 1270FALSE00
2026-10-161.50PUT0 590FALSE00
2026-10-1620PUT0 00FALSE00
2026-10-162.50PUT0 0247.9FALSE00
2026-10-1650PUT0 0163.27FALSE00
2026-10-167.50PUT0 0124.82FALSE00
2026-10-16100PUT0 41164.14FALSE00
2026-10-1612.50PUT0 9135.08FALSE00
2026-10-16150PUT0 0111.5TRUE00
2026-10-1617.50PUT0 0129.99TRUE00
2026-10-16200PUT0 0131.39TRUE00
2026-10-1622.50PUT0 1130.6TRUE00
2026-10-16250PUT0 0131.61TRUE00
2027-01-152.50CALL0 23166.94TRUE00
2027-01-1550CALL0 190.18TRUE00
2027-01-157.50CALL0 192137.51TRUE00
2027-01-15100CALL0 189140.54TRUE00
2027-01-1512.50CALL0 6137.37TRUE00
2027-01-15155.44CALL5 29139.52FALSE5.440
2027-01-1517.50CALL0 2118.08FALSE00
2027-01-15204.39CALL0 76128.43FALSE00
2027-01-1522.50CALL0 1136.93FALSE00
2027-01-15250CALL0 0129.78FALSE00
2027-01-152.50PUT0 0187.96FALSE00
2027-01-1550PUT0 0143.5FALSE00
2027-01-157.50PUT0 2115.95FALSE00
2027-01-15100PUT0 0142.23FALSE00
2027-01-1512.50PUT0 0137.16FALSE00
2027-01-15150PUT0 0141.71TRUE00
2027-01-1517.50PUT0 0142.33TRUE00
2027-01-15200PUT0 0121.55TRUE00
2027-01-1522.50PUT0 0142.55TRUE00
2027-01-15250PUT0 0144.23TRUE00

Latest IMUX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST7$3.125
Jun 13, 2022 7:59 PM EST68$3.125
Jun 13, 2022 7:59 PM EST12$3.125
Jun 13, 2022 7:59 PM EST345$3.125
Jun 13, 2022 7:59 PM EST54$3.125

Immunic, Inc (IMUX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000718/0001193805-20-000718-index.htm
2019-02-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1280776/000000000019002243/0000000000-19-002243-index.htm
2019-02-01SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1280776/000104018819000044/0001040188-19-000044-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000117184319000159/0001171843-19-000159-index.htm
2019-01-07425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1280776/000117184319000160/0001171843-19-000160-index.htm
2018-09-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1280776/000119312518275754/0001193125-18-275754-index.htm
2019-02-04S-4Registration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1280776/000119312519026996/0001193125-19-026996-index.htm
2019-02-06425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1280776/000119312519029598/0001193125-19-029598-index.htm
2019-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1280776/000119312519037823/0001193125-19-037823-index.htm
2019-02-14S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1280776/000119312519039488/0001193125-19-039488-index.htm
2019-02-19424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1280776/000119312519044352/0001193125-19-044352-index.htm
2019-02-26425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1280776/000119312519051970/0001193125-19-051970-index.htm
2019-02-28425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1280776/000119312519057485/0001193125-19-057485-index.htm
2019-03-13DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1280776/000119312519073294/0001193125-19-073294-index.htm
2019-03-14425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1280776/000119312519074766/0001193125-19-074766-index.htm
2019-03-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1280776/000119312519083499/0001193125-19-083499-index.htm
2019-03-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1280776/000119312519085255/0001193125-19-085255-index.htm
2019-03-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1280776/000119312519088450/0001193125-19-088450-index.htm
2019-04-02425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1280776/000119312519095652/0001193125-19-095652-index.htm
2019-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119312519106593/0001193125-19-106593-index.htm
2019-12-20SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1280776/000119312519321092/0001193125-19-321092-index.htm
2020-09-04SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1280776/000119312520240090/0001193125-20-240090-index.htm
2019-04-22SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000386/0001193805-19-000386-index.htm
2019-04-22SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000387/0001193805-19-000387-index.htm
2019-04-22SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000388/0001193805-19-000388-index.htm
2019-04-22SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000389/0001193805-19-000389-index.htm
2019-04-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000397/0001193805-19-000397-index.htm
2019-04-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000398/0001193805-19-000398-index.htm
2019-04-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000399/0001193805-19-000399-index.htm
2019-04-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000400/0001193805-19-000400-index.htm
2019-04-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000401/0001193805-19-000401-index.htm
2019-04-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000402/0001193805-19-000402-index.htm
2019-04-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000404/0001193805-19-000404-index.htm
2019-04-23SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000411/0001193805-19-000411-index.htm
2019-04-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000412/0001193805-19-000412-index.htm
2019-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000554/0001193805-19-000554-index.htm
2019-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000642/0001193805-19-000642-index.htm
2019-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/0001193805-19-000646-index.htm
2019-07-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1280776/000119380519000647/0001193805-19-000647-index.htm
2019-07-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000658/0001193805-19-000658-index.htm
2019-07-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000670/0001193805-19-000670-index.htm
2019-07-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000671/0001193805-19-000671-index.htm
2019-07-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000672/0001193805-19-000672-index.htm
2019-07-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000673/0001193805-19-000673-index.htm
2019-07-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000674/0001193805-19-000674-index.htm
2019-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000700/0001193805-19-000700-index.htm
2019-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000702/0001193805-19-000702-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000717/0001193805-19-000717-index.htm
2019-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/0001193805-19-000797-index.htm
2019-09-20S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/0001193805-19-000837-index.htm
2019-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519000898/0001193805-19-000898-index.htm
2019-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519001337/0001193805-19-001337-index.htm
2019-10-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519001344/0001193805-19-001344-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519001345/0001193805-19-001345-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519001401/0001193805-19-001401-index.htm
2019-11-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519001458/0001193805-19-001458-index.htm
2019-11-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519001463/0001193805-19-001463-index.htm
2019-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519001465/0001193805-19-001465-index.htm
2019-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519001898/0001193805-19-001898-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380519001904/0001193805-19-001904-index.htm
2019-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380519001914/0001193805-19-001914-index.htm
2020-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000018/0001193805-20-000018-index.htm
2020-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000027/0001193805-20-000027-index.htm
2020-01-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000028/0001193805-20-000028-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000363/0001193805-20-000363-index.htm
2020-03-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1280776/000119380520000386/0001193805-20-000386-index.htm
2020-04-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000499/0001193805-20-000499-index.htm
2020-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000504/0001193805-20-000504-index.htm
2020-04-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1280776/000119380520000514/0001193805-20-000514-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000519/0001193805-20-000519-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000532/0001193805-20-000532-index.htm
2020-04-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000538/0001193805-20-000538-index.htm
2020-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000567/0001193805-20-000567-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000575/0001193805-20-000575-index.htm
2020-05-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000603/0001193805-20-000603-index.htm
2020-06-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1280776/000119380520000677/0001193805-20-000677-index.htm
2020-06-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1280776/000119380520000684/0001193805-20-000684-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000688/0001193805-20-000688-index.htm
2020-06-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000706/0001193805-20-000706-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000718/0001193805-20-000718-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000793/0001193805-20-000793-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000794/0001193805-20-000794-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000795/0001193805-20-000795-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000796/0001193805-20-000796-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000797/0001193805-20-000797-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000798/0001193805-20-000798-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000799/0001193805-20-000799-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000800/0001193805-20-000800-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000802/0001193805-20-000802-index.htm
2020-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000879/0001193805-20-000879-index.htm
2020-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000880/0001193805-20-000880-index.htm
2020-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000890/0001193805-20-000890-index.htm
2020-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000918/0001193805-20-000918-index.htm
2020-08-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1280776/000119380520000920/0001193805-20-000920-index.htm
2020-08-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1280776/000119380520000924/0001193805-20-000924-index.htm
2020-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1280776/000119380520000959/0001193805-20-000959-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000975/0001193805-20-000975-index.htm
2020-08-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520000993/0001193805-20-000993-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520001136/0001193805-20-001136-index.htm
2020-09-21SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1280776/000119380520001154/0001193805-20-001154-index.htm
2020-10-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520001296/0001193805-20-001296-index.htm
2020-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000119380520001306/0001193805-20-001306-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000119380520001389/0001193805-20-001389-index.htm
2018-09-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000128077618000089/0001280776-18-000089-index.htm
2018-09-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000128077618000091/0001280776-18-000091-index.htm
2018-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000128077618000093/0001280776-18-000093-index.htm
2018-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000128077618000095/0001280776-18-000095-index.htm
2018-10-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077618000098/0001280776-18-000098-index.htm
2018-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077618000100/0001280776-18-000100-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077618000103/0001280776-18-000103-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1280776/000128077618000104/0001280776-18-000104-index.htm
2019-01-07425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000002/0001280776-19-000002-index.htm
2019-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000008/0001280776-19-000008-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000014/0001280776-19-000014-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000015/0001280776-19-000015-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000016/0001280776-19-000016-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000017/0001280776-19-000017-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000018/0001280776-19-000018-index.htm
2019-01-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000020/0001280776-19-000020-index.htm
2019-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000024/0001280776-19-000024-index.htm
2019-03-0410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1280776/000128077619000025/0001280776-19-000025-index.htm
2019-03-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000027/0001280776-19-000027-index.htm
2019-04-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000030/0001280776-19-000030-index.htm
2019-04-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1280776/000128077619000032/0001280776-19-000032-index.htm
2019-04-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000036/0001280776-19-000036-index.htm
2019-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000039/0001280776-19-000039-index.htm
2019-06-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1280776/000128077619000046/0001280776-19-000046-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1280776/000128077619000051/0001280776-19-000051-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1280776/000128077619000056/0001280776-19-000056-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1280776/000128077620000009/0001280776-20-000009-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1280776/000128077620000015/0001280776-20-000015-index.htm
2020-08-0310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1280776/000128077620000024/0001280776-20-000024-index.htm
2020-08-0310-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1280776/000128077620000028/0001280776-20-000028-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1280776/000128077620000035/0001280776-20-000035-index.htm
2019-06-18DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1280776/000138713119004477/0001387131-19-004477-index.htm
2020-05-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1280776/000138713120004360/0001387131-20-004360-index.htm
2020-08-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1280776/000138713120007254/0001387131-20-007254-index.htm
2019-02-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1280776/999999999519000279/9999999995-19-000279-index.htm
2020-02-10SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1280776/999999999720000619/9999999997-20-000619-index.htm
2020-03-02SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1280776/999999999720001094/9999999997-20-001094-index.htm

Immunic, Inc (IMUX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Immunic, Inc (IMUX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2795%
Institutional Ownership: 4678%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-09-19Douglas Evan GodshallDirectorSell69,375.000.3524,191.060.00https://www.sec.gov/Archives/edgar/data/1280776/000128077618000091/0001280776-18-000091-index.htm
2018-09-25Errol R. HalperinDirectorSell10,000.000.292,900.000.00https://www.sec.gov/Archives/edgar/data/1280776/000128077618000095/0001280776-18-000095-index.htm
2018-09-25Errol R. HalperinDirectorSell89,417.000.2925,939.870.00https://www.sec.gov/Archives/edgar/data/1280776/000128077618000095/0001280776-18-000095-index.htm
2018-09-17Muneer A SatterDirectorSell7,044,777.000.292,054,256.970.00https://www.sec.gov/Archives/edgar/data/1280776/000128077618000089/0001280776-18-000089-index.htm
2020-08-10Glenn WhaleyPFO and PAOBuy1,000.0018.9618,960.001,000.00https://www.sec.gov/Archives/edgar/data/1280776/000119380520000993/0001193805-20-000993-index.htm
2019-12-04Duane NashDirectorSell4,400.006.9630,624.0010,032.00https://www.sec.gov/Archives/edgar/data/1280776/000119380519001904/0001193805-19-001904-index.htm
2018-09-24JEAN JACQUES BIENAIMEDirectorSell26,619.000.308,001.6718,500.00https://www.sec.gov/Archives/edgar/data/1280776/000128077618000093/0001280776-18-000093-index.htm
2019-12-02Duane NashDirectorBuy22,157.0022,362.00https://www.sec.gov/Archives/edgar/data/1280776/000119380519001904/0001193805-19-001904-index.htm
2020-07-21Manfred GroeppelChief Operating OfficerSell650.0015.6210,154.89278,830.00https://www.sec.gov/Archives/edgar/data/1280776/000119380520000880/0001193805-20-000880-index.htm
2020-07-20Manfred GroeppelChief Operating OfficerSell5,000.0014.4472,200.50279,480.00https://www.sec.gov/Archives/edgar/data/1280776/000119380520000880/0001193805-20-000880-index.htm
2020-07-21Daniel VittChief Executive OfficerSell1,300.0015.6220,309.77362,877.00https://www.sec.gov/Archives/edgar/data/1280776/000119380520000879/0001193805-20-000879-index.htm
2020-07-20Daniel VittChief Executive OfficerSell5,000.0014.4472,200.50364,177.00https://www.sec.gov/Archives/edgar/data/1280776/000119380520000879/0001193805-20-000879-index.htm
2018-09-14Muneer A SatterDirectorSell447,500.000.36160,384.007,044,777.00https://www.sec.gov/Archives/edgar/data/1280776/000128077618000089/0001280776-18-000089-index.htm
2018-09-13Muneer A SatterDirectorSell3,890,000.000.501,930,996.007,492,277.00https://www.sec.gov/Archives/edgar/data/1280776/000128077618000089/0001280776-18-000089-index.htm